Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06077214 · ClinicalTrials.gov registry record · Phase 1
Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients
A Phase 1 study of Post Operative Pain and Bariatric Surgery Candidate, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT06077214 is a Phase 1 study of Post Operative Pain and Bariatric Surgery Candidate that has completed, run by Virginia Commonwealth University. The registered enrollment target is 9 participants, below the 236-participant average among 56 other Post Operative Pain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06077214, a Phase 1 study of Post Operative Pain and Bariatric Surgery Candidate, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. Typical length of therapeutic effect for standard bupivacaine is up to 6 hours. The liposomal formulation of bupivacaine, however, has a length of therapeutic effect of up to 72 hours. Typical post-operative incisional pain is known to last for several days in most cases and is thought to peak between 1-2 days after surgery. Therefore, the benefit of most short-acting local analgesics does not overlap with the period of most need.
Conditions Studied
Interventions
- DRUG Treatment with liposomal bupivacaine
- DRUG Treatment with standard bupivacaine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2024-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06077214
The ClinicalTrials.gov registry entry for NCT06077214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 236-participant average among 56 other Post Operative Pain trials with a reported enrollment target (96% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Post Operative Pain appearing as the primary indexed condition, and to 2 interventions - of which Treatment with liposomal bupivacaine is the first listed.
NCT06077214 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06077214 about?
NCT06077214 is a clinical study titled "Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients". Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. Typical length of therapeutic effect for standard bupivacaine is...
What is the current status of trial NCT06077214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-01-31. Estimated completion is 2024-08-20.
What conditions does trial NCT06077214 study?
This clinical trial studies the following conditions: Post Operative Pain, Bariatric Surgery Candidate.
What interventions are being tested in trial NCT06077214?
The interventions under investigation include: Treatment with liposomal bupivacaine (DRUG), Treatment with standard bupivacaine (DRUG).
Who is sponsoring clinical trial NCT06077214?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06077214 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Operative Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease
RECRUITING · Phase 1
-
A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi
RECRUITING · Phase 4
-
Sensory Outcomes in Active Substance Users
RECRUITING
-
Pain With Differing Insufflation Pressures During Laparoscopic Hysterectomy
RECRUITING · NA
-
Preoperative Acetazolamide
RECRUITING · Phase 4
-
Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.